Form 4: uniQure Director Jack Kaye Exercises, Sells Shares

uniQure N.V. Director Jack Kaye executed pre-planned transactions, exercising stock options and subsequently selling 38,810 ordinary shares for a significant profit.

Summary

• Jack Kaye, a Director of uniQure N.V. (QURE), reported multiple transactions on November 4, 2025.
• These transactions were conducted under a Rule 10b5-1 sales plan adopted on June 16, 2025.
• Kaye exercised stock options to acquire a total of 38,810 ordinary shares.
• The exercise prices for these options were $7.37 (10,000 shares), $5.37 (11,000 shares), and $14.08 (17,810 shares).
• Concurrently, Kaye sold all 38,810 shares acquired through these exercises.
• The sales occurred at weighted average prices of $30.36, $30.34, and $30.33, respectively.
• Following these transactions, Kaye's direct beneficial ownership of ordinary shares is 20,439.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a 10b5-1 plan, indicating a systematic approach to personal financial management rather than a lack of confidence in the company. The significant profit realized by the director also reflects positively on the company's stock performance over the vesting periods.

Positives

• Director Jack Kaye realized substantial profits from exercising deeply in-the-money stock options and selling the shares.
• The sales were executed at prices significantly higher than the option exercise prices, indicating a strong appreciation in uniQure's stock value over the vesting periods of the options.
• The transactions were pre-planned under a Rule 10b5-1 plan, suggesting a systematic approach to managing personal holdings rather than a reaction to immediate company news.

Negatives

• A director selling a significant number of shares, even if pre-planned, could be perceived negatively by some investors as it reduces insider ownership.

Future Outlook

NA

Industry Context

This Form 4 filing reflects a routine insider transaction under a pre-arranged trading plan, common among executives and directors in the biotechnology and pharmaceutical sectors for personal financial planning and diversification. It does not inherently signal a change in company fundamentals or industry trends, but rather a director monetizing long-held equity compensation.

Stakeholder Impact

• Shareholders: May view the director's profit-taking positively as it reflects stock appreciation, but some might see the reduction in insider ownership as a slight negative. The pre-planned nature mitigates concerns.
• Employees: No direct impact.
• Customers/Suppliers/Creditors: No direct impact.

Key Dates

Recommendation

The filing details a pre-planned insider sale by a director, which is a routine event for personal financial management and does not typically signal a change in the company's fundamental outlook. The director realized significant profits, indicating past stock appreciation. However, the reduction in insider ownership, while pre-planned, does not provide a strong catalyst for a 'buy' recommendation, nor does it suggest a 'sell' given the context of a 10b5-1 plan. Therefore, a 'hold' recommendation is appropriate as this filing alone does not alter the investment thesis for uniQure N.V.

Keywords

uniQure N.V., QURE, Jack Kaye, Director, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1, Beneficial Ownership